

FORM 51-102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company:

BIOWEST THEREAPEUTICS INC.
#400 – 1727 West Broadway
Vancouver, British Columbia V6J 4W6

2. Date of Material Change:

The material change described in this report occurred on February 2, 2011.

3. News Release:

On February 2, 2011, BioWest Therapeutics Inc. (the "**Company**"), issued a news release through the facilities of Filing Services Canada. A copy of the news release announcing the material change is set out at Schedule "A" to this report.

4. Summary of Material Change:

On February 2, 2011, the Company announced that Ann Fehr had been appointed as chief financial officer of the Company upon the resignation of Jeff Charpentier.

5. Full Description of Material Change:

See attached news release at Schedule "A" to this report.

6. Reliance on Confidential Filing Provisions:

Not applicable.

7. Omitted Information:

Not applicable.

8. Executive Officer:

The following executive officer of the Company is knowledgeable about the material change and this report and may be contacted respecting the material change and this report:

Contact: Bruce Schmidt
Tel: (604) 221-9666

9. Date of Report:

February 4, 2011.

SCHEDULE "A"



FOR IMMEDIATE RELEASE

Toronto Stock Exchange: BWE

BIOWEST THERAPEUTICS ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

Vancouver, British Columbia, Canada/February 2, 2011/ -- BioWest Therapeutics Inc. ("BioWest" or the "Company"), is pleased to announce that Ann Fehr has been appointed as chief financial officer of the Company. Ms. Fehr is a Certified General Accountant with over 14 years of experience as a senior manager. Ms. Fehr is well versed in the corporate governance and regulatory financial reporting for publicly traded companies. She currently serves as chief financial officer for Global Minerals Ltd., New High Ridge Resources and Global Uranium.

Jeff Charpentier has resigned from his position as chief financial officer of the Company to pursue other career opportunities. The board of directors thanks Mr. Charpentier for his contributions to BioWest and wishes him all the best in the future.

Contact: Bruce Schmidt
Tel: (604) 221-9666

About BioWest

BioWest is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the treatment of unmet medical needs for various diseases. The Company's programs include drug candidates for: the prevention of catheter related infections, for the treatment of hospital-acquired infections, the treatment of dermatological diseases, and the treatment of hepatitis B infections. BioWest is headquartered in Vancouver, British Columbia, Canada.